| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
|
J Exp Med
|
2006
|
4.84
|
|
2
|
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
|
Cancer Immunol Immunother
|
2009
|
3.70
|
|
3
|
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
|
Clin Cancer Res
|
2005
|
3.57
|
|
4
|
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
|
J Clin Oncol
|
2004
|
3.11
|
|
5
|
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
|
Cancer Res
|
2004
|
2.91
|
|
6
|
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
|
Cancer Res
|
2004
|
2.54
|
|
7
|
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
|
J Immunol
|
2003
|
2.51
|
|
8
|
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
|
Clin Cancer Res
|
2008
|
1.83
|
|
9
|
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
|
Cancer Res
|
2002
|
1.77
|
|
10
|
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
|
Expert Opin Investig Drugs
|
2009
|
1.71
|
|
11
|
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
|
Clin Cancer Res
|
2008
|
1.59
|
|
12
|
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
|
Clin Cancer Res
|
2005
|
1.49
|
|
13
|
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
|
Oncotarget
|
2014
|
1.49
|
|
14
|
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.
|
Front Oncol
|
2012
|
1.43
|
|
15
|
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
|
Clin Cancer Res
|
2006
|
1.36
|
|
16
|
Selective induction of high avidity CTL by altering the balance of signals from APC.
|
J Immunol
|
2003
|
1.34
|
|
17
|
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
|
Int J Cancer
|
2011
|
1.34
|
|
18
|
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
|
Clin Cancer Res
|
2005
|
1.20
|
|
19
|
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
|
Cancer Immunol Immunother
|
2011
|
1.18
|
|
20
|
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
|
Mol Biosyst
|
2009
|
1.16
|
|
21
|
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
|
Cancer Immunol Res
|
2013
|
1.16
|
|
22
|
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
|
Clin Cancer Res
|
2013
|
1.15
|
|
23
|
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
|
Clin Cancer Res
|
2008
|
1.14
|
|
24
|
Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
|
PLoS One
|
2013
|
1.14
|
|
25
|
Vaccines with enhanced costimulation maintain high avidity memory CTL.
|
J Immunol
|
2005
|
1.12
|
|
26
|
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
|
Clin Cancer Res
|
2008
|
1.09
|
|
27
|
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
|
Crit Rev Immunol
|
2007
|
1.07
|
|
28
|
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
|
Cancer Res
|
2002
|
1.04
|
|
29
|
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
|
Vaccine
|
2007
|
1.04
|
|
30
|
Combining radiation and immunotherapy for synergistic antitumor therapy.
|
Curr Opin Mol Ther
|
2009
|
1.03
|
|
31
|
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
|
Vaccine
|
2006
|
1.02
|
|
32
|
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
|
J Immunol
|
2013
|
1.01
|
|
33
|
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
|
Int J Cancer
|
2010
|
1.00
|
|
34
|
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
|
Cancer Gene Ther
|
2004
|
0.98
|
|
35
|
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
|
Cancer Immunol Immunother
|
2009
|
0.98
|
|
36
|
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
|
Oncotarget
|
2013
|
0.98
|
|
37
|
Cancer vaccines: preclinical studies and novel strategies.
|
Adv Cancer Res
|
2006
|
0.96
|
|
38
|
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
|
Cancer Immunol Immunother
|
2008
|
0.96
|
|
39
|
Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.
|
Radiat Res
|
2014
|
0.95
|
|
40
|
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.
|
Cancer Biother Radiopharm
|
2014
|
0.95
|
|
41
|
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
|
Clin Cancer Res
|
2013
|
0.92
|
|
42
|
Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.
|
Expert Rev Vaccines
|
2013
|
0.91
|
|
43
|
Vaccines based on whole recombinant Saccharomyces cerevisiae cells.
|
FEMS Yeast Res
|
2010
|
0.91
|
|
44
|
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
45
|
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
|
Clin Cancer Res
|
2004
|
0.90
|
|
46
|
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.
|
Radiat Res
|
2014
|
0.90
|
|
47
|
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
|
Cancer Immunol Immunother
|
2007
|
0.89
|
|
48
|
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
|
Clin Cancer Res
|
2007
|
0.88
|
|
49
|
TRICOM vector based cancer vaccines.
|
Curr Pharm Des
|
2006
|
0.87
|
|
50
|
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.
|
Cell Immunol
|
2003
|
0.86
|
|
51
|
Vaccines as monotherapy and in combination therapy for prostate cancer.
|
Clin Transl Sci
|
2010
|
0.85
|
|
52
|
Synergistic antitumor activity of immune strategies combined with radiation.
|
Front Biosci
|
2007
|
0.85
|
|
53
|
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
|
Blood
|
2005
|
0.85
|
|
54
|
Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
|
Cancer Biother Radiopharm
|
2012
|
0.84
|
|
55
|
Harnessing the potential of radiation-induced immune modulation for cancer therapy.
|
Cancer Immunol Res
|
2013
|
0.84
|
|
56
|
Enhancing immune responses to tumor-associated antigens.
|
Cancer Biol Ther
|
2009
|
0.84
|
|
57
|
Immunobiology of radiotherapy: new paradigms.
|
Radiat Res
|
2014
|
0.84
|
|
58
|
Combining Vaccines with Conventional Therapies for Cancer.
|
Update Cancer Ther
|
2007
|
0.82
|
|
59
|
In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation.
|
Radiat Res
|
2014
|
0.82
|
|
60
|
Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.
|
Cancer Res
|
2014
|
0.81
|
|
61
|
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
|
Cancer Immunol Immunother
|
2007
|
0.77
|
|
62
|
Introduction: Therapeutic cancer vaccines.
|
Semin Oncol
|
2012
|
0.75
|